Skip to main content
OpenTrials
Completed

NCT Number: NCT03614975

Immunologic Response to Influenza Vaccination in Children and Adolescents

The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-20 years of age. This is a randomized controlled trial (RCT), that will assess immune response in 120 participants (60 per vaccine arm) pre- and post-vaccination to Flucelvax (egg-free inactivated flu shot) and Fluzone (egg-based inactivated flu shot).

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

General Academic Pediatrics, Pittsburgh, Pennsylvania, United States

Loading trial locations.

About this study

This is a non-blinded, randomized controlled trial analyzing influenza vaccine immunogenicity response in children/adolescents/young adults aged 4-20 years given one of two FDA approved and licensed influenza vaccines: Flucelvax (egg-free inactivated flu shot) and Fluzone (egg-based inactivated flu shot). This study will enroll 120 healthy participants, 60 per vaccine arm. Participants will be randomized using a 1:1 allocation to receive either Flucelvax or Fluzone. Blood work will be conducted on all participants at baseline prior to vaccine receipt and post-vaccination at Day 7 (range 6-9 days) and Day 21 (range 21-35 days). The primary objective of the study is to determine pre and post serologic,responses to each vaccine type.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 4-20 years;
  • has prior vaccination history available (which can be determined based either on medical record review or through state registry review;
  • plans to receive the current seasonal influenza vaccination at one of the recruiting sites

Exclusion criteria

  • unable or unwilling to completed required study activities, including informed consent, randomization to vaccine, and bloodwork;
  • has already received influenza vaccine for the current season;
  • has a known immunocompromising condition or is on an immunosuppressing medication (e.g., high dose steroids >10 days);
  • is known to be pregnant;
  • has a history of severe allergy to eggs or to influenza vaccine or any of its components

Treatment and study plan

Flucelvax inactivated influenza vaccine

Biological

Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)

Fluzone inactivated influenza vaccine

Biological

Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)

Primary outcomes

  1. Determining Seroconversion Response - Change in HI Titers From Pre- to Post Vaccination

    Time frame: Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 21 timepoint)

    Hemagglutination inhibition (HI) assay will be conducted to assess immunologic outcome. Seroconversion is defined as a 4-fold or higher rise in HI titer post-vaccination given a pre-vaccination HI titer of >= 10.

Secondary outcomes

  1. Determining Seroprotection Level at Each Time Point

    Time frame: Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 21 timepoint)

    Hemagglutination inhibition assay will be conducted to assess immunologic outcome. Seroprotection is defined as a HI titer >= 1:110 at either time point.

  2. Determining Geometric Mean Titers (GMTs) at Each Time Point

    Time frame: Pre-vaccination (at Day 0 timepoint) and post-vaccination (at Day 21 timepoint)

    Hemagglutination inhibition assay will be conducted to assess immunologic outcome. GMTs is defined as the anti-log of the mean of the log2 HI titers

Sponsors and collaborators

Lead sponsor

Richard Zimmerman MD

Other

Collaborators

  • Centers for Disease Control and Prevention

Registry information

Official study title

Immunologic Response to Influenza Vaccination in Children and Adolescents: A RCT Trial of Influenza Vaccines

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 3, 2018
Registry last updated
Jan 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.